BerandaAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
$3,82
Setelah Jam Perdagangan Normal:(0,00%)0,00
$3,82
Tutup: 16 Apr, 16.01.43 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$3,88
Rentang hari
$3,79 - $3,93
Rentang tahun
$1,58 - $7,26
Kapitalisasi pasar
338,46Â jt USD
Volume Rata-Rata
813,47Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | -665,00Â rb | -100,61% |
Biaya operasional | 53,30Â jt | 2,03% |
Laba bersih | -37,55Â jt | -893,62% |
Margin laba bersih | 5,65Â rb | 129.395,87% |
Penghasilan per saham | -0,55 | -885,71% |
EBITDA | -40,49Â jt | -1.911,81% |
Tarif pajak efektif | 1,66% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 176,50Â jt | -52,47% |
Total aset | 193,63Â jt | -62,58% |
Total liabilitas | 28,87Â jt | -65,64% |
Total ekuitas | 164,76 jt | — |
Saham yang beredar | 88,60 jt | — |
Harga terhadap nilai buku | 1,62 | — |
Tingkat pengembalian aset | -45,75% | — |
Tingkat pengembalian modal | -55,61% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -37,55Â jt | -893,62% |
Kas dari operasi | -59,01Â jt | -535,45% |
Kas dari investasi | 64,98Â jt | 210,54% |
Kas dari pembiayaan | 110,00Â rb | -52,17% |
Perubahan kas bersih | 5,56Â jt | -84,10% |
Arus kas bebas | -45,65Â jt | -239,09% |
Tentang
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Didirikan
2013
Situs
Karyawan
123
